WO2004063181A1 - Urea derivatives and their use as anti-inflammatory agents - Google Patents

Urea derivatives and their use as anti-inflammatory agents Download PDF

Info

Publication number
WO2004063181A1
WO2004063181A1 PCT/US2003/041470 US0341470W WO2004063181A1 WO 2004063181 A1 WO2004063181 A1 WO 2004063181A1 US 0341470 W US0341470 W US 0341470W WO 2004063181 A1 WO2004063181 A1 WO 2004063181A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
group
aryl
substituted
formula
Prior art date
Application number
PCT/US2003/041470
Other languages
French (fr)
Inventor
Mark M. Staveski
Robert Miller
Sharon R. Nahill
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Priority to AU2003303678A priority Critical patent/AU2003303678A1/en
Publication of WO2004063181A1 publication Critical patent/WO2004063181A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/12—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/14—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/64—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups singly-bound to oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/58—Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Definitions

  • This invention relates to compositions and methods of modulating an inflammatory or immune response.
  • Ethyl dimethylaminopropylurea (1 ) (EDU) has been shown to be effective in preventing sepsis and its mode of action has been linked to the inhibition of Concanavalin A activated T-cell proliferation.
  • EDU a series of analogs of EDU (see formula I described below) have now been prepared and shown to be active agents against a modified Concanavalin A activated T-cell proliferation assay using purified rat T cells.
  • Compounds from this series showed in-vivo activity in a rat model of inflammatory bowel disease (IBD), a mouse model of septic shock, and a mouse model of autoimmune encephalomyelitis (EAE). This in-vivo activity coupled with lack of cellular toxicity and in-vivo toxicity demonstrate that these types of compounds can be used as anti-inflammatory agents in immune responses.
  • IBD inflammatory bowel disease
  • EAE autoimmune encephalomyelitis
  • T-cell proliferation is an immune response indicative of inflammatory processes such as those found in IBD, EAE, sepsis, rheumatoid arthritis and lupus. Therefore, compounds of the present invention are useful in the treatment or management of inflammatory responses or diseases such as treatment of sepsis, IBD, EAE, and lupus for example.
  • R 1 is a lower C2-C5 alkyl group, straight or branched chain and optionally substituted by an amino group of formula -NR 3 R 4 , wherein R 3 and R 4 are independently H, or C1-C3 alkyl group;
  • Q is either a bond or a divalent C1-C5 straight or branched alkyl or alkenyl group
  • R 2 is either one or more of the following groups a. H, adamantyl, -OH provided that R 2 is not a bond, b. OR 5 , -COR 5 , -CO 2 R 5 wherein R 5 is a C1-C4 straight or branched alkyl group, c. C6-C10 aryl group, d. C5-C10 heteroaryl group wherein one or more ring positions may be occupied by N, S, or O, e.
  • R 5 -CN, halogen, OR 5 , -COR 5 , -CO 2 R 5 , OCF 3 , -CONH 2 , -SO 2 NH 2 , wherein R 5 is a C1-C4 straight or branched alkyl group,
  • Figure 1 is a plot of the assessment of the disease severity score
  • ADSS ADSS over time post challenge in a mouse model of EAE for control (vehicle) and treated with a compound of the invention.
  • Figure 2 is a plot of the assessment of the disease severity score (ADSS) over time post challenge in a mouse model of EAE for control (vehicle) and treated with a compound of the invention at two doses.
  • ADSS disease severity score
  • formula I includes compounds of formula II, formula II and formula IV and pharmaceutically acceptable salts thereof as set out below:
  • illustrative examples of a C2-C5 alkyl include, but are not limited to, ethyl, propyl, isopropyl, butyl, 2-butyl, pentyl, 2-pentyl, 3-pentyl, and terbutyl.
  • a C1-C3 alkyl group includes methyl, ethyl, propyl, and isopropyl.
  • illustrative examples of NR 3 R 4 include amino, methyl amino, dimethyl amino, ethyl amino, dimethyl amino, ethyl, methyl amino, propylamino, methylpropylamino, ethylpropylamino, dipropylamino, isopropylamino, methylisopropyl amino, ethylisopropyl amino, and diisopropylamino.
  • Preferred R 1 groups include ethyl and dimethylaminopropyl group.
  • illustrative examples of a C2-C5 straight or branched alkyl include, but are not limited to, ethyl, propyl, isopropyl, butyl, 2- butyl, pentyl, 2-pentyl, 3-pentyl, and terbutyl; and illustrative examples of a C2-C5 straight or branched alkenyl include, but are not limited to, ethylene, propylene, propyl- 2-ene, isopropylene, butyl-1-ene, butyl-2-ene, butyl-3-ene, 2-methyl-propyl-2-ene, 2- methylpropy-1-ene, butadiene, pentyl-1 -ene, pentyl-2-ene, pentyl-3-ene, pentyl-4-ene, 2-methylbutadiene, 3-methylbutadiene, 1 ,3-penta
  • Divalence positions on these groups may be obtained by the removal of two hydrogen atoms from any carbon positions including the following combinations whenever applicable to the alkyl or alkylene group (C1 ,C1 ), (C1 ,C2), (C1 , C3), (C1 ,C4), (C1 ,C5), (C2.C2), (C2.C3), (C2.C4), (C2.C5), (C3.C3), (C3.C4), (C3.C5), (C4.C4), (C4.C5), and (C5, C5).
  • illustrative examples of a C2-C4 straight or branched alkyl include, but are not limited to, ethyl, propyl, isopropyl, butyl, and 2-butyl;
  • illustrative example of a C6-C10 aryl group include, but are not limited to, phenyl, 1-naphthyl, 2-naphtlyl;
  • illustrative examples of C5-C10 heterocyclic rings include, but are not limited to, piperidyl, pyrrolidyl, piperazyl, morpholine, tetahydrofuranyl, dioxanyl;
  • heteroaryl group include, but are not limited to, furanyl, thiophenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, dithiolyl, oxathiolyl, iso
  • R 2 examples include but are not limited to, 2-toluyl, 3- toluyl, 4-toluyl, 2,3-xylyl, 2,4-xylyl, 2,5-yiyl, 2,6-xylyl, 3,4-xylyl, 2,4,6-trimethylphenyl, 2- methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3-dimethoxyphenyl, 2,4- dimethoxyphenyl, 2,5-dimethoxyphenyl, 2,6-dimethoxyphenyl, 2-chlorophenyl, 3- chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2,5- dichlorophenyl, 2,6-dichlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3- difluorophen
  • NR 6 R 7 groups of formulas I, and III above include, but are not limited to, N-cyclopropylmethyl-N-propylamino, piperazyl, piperidyl, pirimidyl, morpholyl, thiomorpholyl, oxazinanyl and thiazinanyl.
  • a "subject” includes mammals, e.g., humans, companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like).
  • the subject is human.
  • a subject in need of treatment is suffering from a disease or condition, the symptoms of which may be alleviated by inhibiting T-cell proliferation.
  • a subject will be treated for a disease that is caused, at least in part, by or involves T-cell proliferation.
  • the method is used to improve symptoms in a subject suffering from IBD, EAE, sepsis, rheumatoid arthritis or lupus.
  • the method is used to treat a subject that has IBD or sepsis.
  • the compounds may be administered to a mammal in need of treatment by any route, such as oral, pulmonary, rectal, transdermal, subcutaneous, intravenous, intramuscular, intracranial, intraperitoneal and intranasal in combination with an acceptable pharmaceutical carrier, for tableting, solubilizing, or suspending in emulsion form or for delivering by slow release from a polymeric matrix.
  • an acceptable pharmaceutical carrier for tableting, solubilizing, or suspending in emulsion form or for delivering by slow release from a polymeric matrix.
  • an "effective amount" of a compound of the disclosed invention is the quantity which, when administered to a subject in need of treatment, improves the prognosis of the subject, e.g., delays the onset of and/or reduces the severity of one or more of the subject's symptoms.
  • the amount of the disclosed compound to be administered to a subject will depend on the particular disease, the mode of administration, and the characteristics of the subject, such as general health, other diseases, age, sex, genotype, body weight and tolerance to drugs. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. Effective amounts of the disclosed compounds typically range between about 0.01 mg/kg per day and about 100 mg/kg per day, and preferably between 0.1 mg/kg per day and about 10 mg/kg/day.
  • Preferably disclosed compounds or pharmaceutical formulations containing these compounds are in unit dosage form for administration to a subject.
  • the unit dosage form can be any unit dosage form known in the art including, for example, a capsule, an I.V. bag, a tablet, a single pump on an aerosol inhaler, or a vial.
  • the quantity of active ingredient (i.e., a compound of structural formula I or salts thereof) in a unit dose of composition is an effective amount and may be varied according to the particular treatment involved. It may be appreciated that it may be necessary to make routine variations to the dosage depending on the age and condition of the patient.
  • the dosage will also depend on the route of administration which may be by a variety of routes as outlined above.
  • a "pharmaceutically acceptable salt” of the disclosed compound can be used in the disclosed methods.
  • an acid salt of a compound containing an amine or other basic group can be obtained by reacting the compound with a suitable organic or inorganic acid, such as hydrogen chloride, hydrogen bromide, acetic acid, perchloric acid and the like.
  • a suitable organic or inorganic acid such as hydrogen chloride, hydrogen bromide, acetic acid, perchloric acid and the like.
  • Compounds with a quaternary ammonium group also contain a counteranion such as chloride, bromide, iodide, acetate, perchlorate and the like.
  • salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g. (+)-tartrates, (-)-tartrates or mixtures thereof including racemic mixtures), succinates, benzoates and salts with amino acids such as glutamic acid.
  • the compounds described herein, and the pharmaceutically acceptable salts thereof can be used in pharmaceutical preparations in combination with a pharmaceutically acceptable carrier or diluent.
  • suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions.
  • the compounds will be present in such pharmaceutical compositions in amounts sufficient to provide the desired dosage amount in the range described herein. Techniques for formulation and administration of the compounds of the instant invention can be found in Remington: the Science and Practice of Pharmacy, 19 th edition, Mack Publishing Co., Easton, PA (1995).
  • the disclosed compounds or salts thereof can be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, pills, suppositories, powders, syrups, solutions, suspensions and the like.
  • the tablets, pills, capsules, and the like contain from about 1 to about 99 weight percent of the active ingredient and a binder such as gum tragacanth, acacias, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch or alginic acid; a lubricant such as magnesium stearate; and/or a sweetening agent such as sucrose, lactose or saccharin.
  • a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.
  • tablets may be coated with shellac, sugar or both.
  • a syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propyl parabens as preservatives, a dye and a flavoring such as cherry or orange flavor, and the like.
  • aqueous or organic media for parenteral administration of the disclosed compounds, or salts thereof, can be combined with sterile aqueous or organic media to form injectable solutions or suspensions.
  • injectable solutions or suspensions for example, solutions in sesame or peanut oil, aqueous propylene glycol and the like can be used, as well as aqueous solutions of water-soluble pharmaceutically-acceptable salts of the compounds.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the compounds may also be formulated as a depot preparation.
  • Suitable formulations of this type include biocompatible and biodegradable polymeric hydrogel formulations using crosslinked or water insoluble formulations of polysaccharides, polyethylene oxides, polyacrylates, and the like.
  • Such long acting formulations may be administered by implantation, for example, subcutaneously or intramuscularly or by intramuscular injection. Preferably, they are implanted in the microenvironment of an affected organ or tissue.
  • the compounds may be formulated with suitable polymeric or hydrophobic materials, for example, as an emulsion in an acceptable oil, or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • the compounds may also be formulated as a topical preparation. Suitable formulations of this type include biocompatible oil, wax, gel, powder, polymer, or other liquid or solid carriers. Such formulations may be administered by applying directly to affected tissues.
  • the compounds may also be formulated as suppositories. Suitable formulations include biocompatible wax.
  • Preferred embodiments of the compounds of this inventions are outlined in the following tables with their in-vitro assay results assessing T-cell response.
  • Step 1 To a stirred solution of amine dissolved in methylene chloride at room temperature is added dropwise 3-bromopropyl isocyanate dissolved in methylene chloride. The reaction is allowed to stir overnight. The reaction was partitioned between methylene chloride and aqueous saturated sodium bicarbonate. The organic layer is separated, washed with brine, dried over sodium sulfate and concentrated.
  • Step 2 The product from Step 1 is dissolved in excess 2.0M dimethylamine in tetrahydrofuran. The reaction is warmed to 45°C and let stir overnight. The reaction is concentrated and partitioned between methylene chloride and aqueous saturated sodium bicarbonate. The organic layer is separated, washed with brine, dried over sodium sulfate and concentrated.
  • Example 8 Synthesis of Compound no. 57 (Fumarate salt of Compound no. 31 )
  • Step 1 To a stirred solution of 1-aminoisoquinoline (2.5 g, 17.3 mmol) in methylene chloride (50 ml) was added 3-bromopropyl isocyanate (3.13 g, 19 mmol) dissolved in methylene chloride (15 ml). The mixture was allowed to stir at room temperature overnight. The mixture was partitioned between methylene chloride (20 ml) and aqueous saturated sodium bicarbonate (20 ml). The organic layer was separated and washed with brine, dried over sodium sulfate and concentrated to give 4.97 g of a brown solid (92%). This was used directly in the next step.
  • Step 2 The 1-(3'-bromopropyl)-3-isoquinolin-1-yl urea from step 1 was dissolved in excess 2M dimethylamine in tetrahydrofuran (10 ml) in a sealed tube. Warmed to 50°C and let stir overnight. The reaction mixture was partitioned between diethyl ether (75 ml) and aqueous saturated sodium bicarbonate (25 ml). The organic layer was separated and washed with brine, dried over sodium sulfate and concentrated. Flash chromatography over silica gel (10:1 methylene chloride/2M ammonia in methanol) provided 3.12 g (70%) of an off-white solid.
  • Example 11 Cytokine Inhibition with compound no. 56 Table 5.
  • Compound no. 56 showed dose responsive activity and statistically significant response at the highest dose (25 mg/kg).
  • Compound no. 56 showed dose responsive activity and statistically significant response at the highest dose (25 mg/kg).
  • PBS PBS 139-151 (50 ⁇ g/mouse) dissolved in PBS and emulsified with an equal volume of
  • ADSS disease severity score

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides compositions and their use in the treatment of inflammatory diseases caused by T-cell proliferation such as sepsis, inflammatory bowel diseases, autoimmune encephalomyelitis, or lupus. The compositions comprise disubstituted ureas of Formulas I, II, III or IV: Formula I: R1-NH-CO-NH-Q-R2, Formula (II): Et-NH-CO-NH-Q-R2, Formula (III): Et-NH-CO-NH-(CH2)3-NR6R7, Formula (IV): Me2N(CH2)3-NH-CO-NH-Q-R2.

Description

UREA DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS
[001] This application claims priority from U.S. provisional application No. 60/437,954 filed on January 3, 2003.
Description of Invention
Field of the Invention
[002] This invention relates to compositions and methods of modulating an inflammatory or immune response. Background of Invention
[003] In WO00/59490, Ethyl dimethylaminopropylurea (1 ) (EDU) has been shown to be effective in preventing sepsis and its mode of action has been linked to the inhibition of Concanavalin A activated T-cell proliferation.
Figure imgf000002_0001
Summary of the Invention
[004] Therefore, a series of analogs of EDU (see formula I described below) have now been prepared and shown to be active agents against a modified Concanavalin A activated T-cell proliferation assay using purified rat T cells. Compounds from this series showed in-vivo activity in a rat model of inflammatory bowel disease (IBD), a mouse model of septic shock, and a mouse model of autoimmune encephalomyelitis (EAE). This in-vivo activity coupled with lack of cellular toxicity and in-vivo toxicity demonstrate that these types of compounds can be used as anti-inflammatory agents in immune responses. T-cell proliferation is an immune response indicative of inflammatory processes such as those found in IBD, EAE, sepsis, rheumatoid arthritis and lupus. Therefore, compounds of the present invention are useful in the treatment or management of inflammatory responses or diseases such as treatment of sepsis, IBD, EAE, and lupus for example.
Formula I:
R1-NH-CO-NH-Q-R2 (I) or a pharmaceutically acceptable salt thereof, wherein
R1 is a lower C2-C5 alkyl group, straight or branched chain and optionally substituted by an amino group of formula -NR3R4, wherein R3 and R4 are independently H, or C1-C3 alkyl group;
Q is either a bond or a divalent C1-C5 straight or branched alkyl or alkenyl group;
R2 is either one or more of the following groups a. H, adamantyl, -OH provided that R2 is not a bond, b. OR5, -COR5, -CO2R5 wherein R5 is a C1-C4 straight or branched alkyl group, c. C6-C10 aryl group, d. C5-C10 heteroaryl group wherein one or more ring positions may be occupied by N, S, or O, e. C5-C10 heterocyclic group wherein one or more ring positions may be occupied by N, S, or O, wherein the aryl, heteroaryl, or heterocyclic ring is unsubstituted or substituted by one or more of the following groups i. R5, -CN, Halogen, OR5, -COR5, -CO2R5, OCF3, -CONH2, -SO2NH2, and NO2, wherein R5 is a C1-C4 straight or branched alkyl group, and f. NR6R7, wherein R6 and R7 are i. independently a C1-C5 straight or branched alkyl or unsubstituted or substituted by -OH or cyclopropyl, phenyl ii. together with the N forming a 5- or 6-membered monocyclic ring having one or more ring positions occupied by another N, S, or O, wherein the heteroaryl ring thus formed is unsubstituted or substituted by one or more of the following groups
1. R5, -CN, halogen, OR5, -COR5, -CO2R5, OCF3, -CONH2, -SO2NH2, wherein R5 is a C1-C4 straight or branched alkyl group,
2. C1-C5 alkyl or alkylene group substituted by an aryl group, and
3. C6 or C10 aryl or heteroaryl group unsubstituted or substituted by one ore more of R5 as defined above, CF3, and halogen, wherein the aryl or hetero aryl may be a pending group off one position of, or a fused with, the NR6R7 ring.
Brief Description of the Drawings
[005] Figure 1 is a plot of the assessment of the disease severity score
(ADSS) over time post challenge in a mouse model of EAE for control (vehicle) and treated with a compound of the invention.
[006] Figure 2 is a plot of the assessment of the disease severity score (ADSS) over time post challenge in a mouse model of EAE for control (vehicle) and treated with a compound of the invention at two doses.
Detailed description of invention
[007] Compounds of Formula I (above), based on an ethyl dimethylaminopropylurea (1) parent structure, have been discovered as active agents against a modified Concanavalin A activated T-cell proliferation assay using purified rat T-cells. These cells were incubated for 4 days and pulsed with [3H] thymidine for the last 16 hrs of incubation. [3H] Thymidine uptake was measured as the mean counts per minute (cpm) of duplicate experimental cultures. The compounds of the present invention were discovered by screening a compound library (directed analogs of parent compound 1 ) using an assay designed to identify inhibitors of Concanavalin A stimulated T-cell proliferation. Normal dermal fibroblasts and kidney epithelial cell toxicity assays were run on active compounds to eliminate non-selective cytotoxic compounds.
[008] Compounds comprising the present invention are listed in the following tables along with their respective screening data. It was found that the bioactivity of the urea is mainly improved when substituents are introduced. The scope of these substitutions, which include substitutions to either the ethyl or dimethylaminomethyl portion of the compound 1 , is illustrated in Tables 1-3. Table 4 lists salt forms that were made from selected analogs. While the T-cell proliferation assay is commonly used for assessing T-cell response, it reveals little about the functional capabilities of the T-cells that respond to it. These must be determined by running functional assays. Towards this end, a selected compound was evaluated against a panel of cytokines and is summarized in Table 5.
[009] More specifically, preferred embodiments of formula I include compounds of formula II, formula II and formula IV and pharmaceutically acceptable salts thereof as set out below:
Formula (II): Et-NH-CO-NH-Q-R2
Formula (III): Et-NH-CO-NH-(CH2)3-NR6R7
Formula (IV): Me2N-(CH2)3-NH-CO-NH-Q-R2
Wherein Q, R2, and NR6R7 are as defined above. [010] In R1 of formula I above, illustrative examples of a C2-C5 alkyl include, but are not limited to, ethyl, propyl, isopropyl, butyl, 2-butyl, pentyl, 2-pentyl, 3-pentyl, and terbutyl. A C1-C3 alkyl group includes methyl, ethyl, propyl, and isopropyl. Thus, illustrative examples of NR3R4, include amino, methyl amino, dimethyl amino, ethyl amino, dimethyl amino, ethyl, methyl amino, propylamino, methylpropylamino, ethylpropylamino, dipropylamino, isopropylamino, methylisopropyl amino, ethylisopropyl amino, and diisopropylamino. Preferred R1 groups include ethyl and dimethylaminopropyl group.
[011] In Q of formulas I, II and IV above, illustrative examples of a C2-C5 straight or branched alkyl include, but are not limited to, ethyl, propyl, isopropyl, butyl, 2- butyl, pentyl, 2-pentyl, 3-pentyl, and terbutyl; and illustrative examples of a C2-C5 straight or branched alkenyl include, but are not limited to, ethylene, propylene, propyl- 2-ene, isopropylene, butyl-1-ene, butyl-2-ene, butyl-3-ene, 2-methyl-propyl-2-ene, 2- methylpropy-1-ene, butadiene, pentyl-1 -ene, pentyl-2-ene, pentyl-3-ene, pentyl-4-ene, 2-methylbutadiene, 3-methylbutadiene, 1 ,3-pentadiene, 2,4-pentadiene. Divalence positions on these groups may be obtained by the removal of two hydrogen atoms from any carbon positions including the following combinations whenever applicable to the alkyl or alkylene group (C1 ,C1 ), (C1 ,C2), (C1 , C3), (C1 ,C4), (C1 ,C5), (C2.C2), (C2.C3), (C2.C4), (C2.C5), (C3.C3), (C3.C4), (C3.C5), (C4.C4), (C4.C5), and (C5, C5). Preferred examples for Q includes in addition to a bond, the following groups: -CH2-, - (CH2)2-, -(CH2)3-, -(CH2)4-, -C(CH2)2-CH2-, -CH2-C(CH3)2-CH2-, and -CH2-CH=CH-.
[012] In R2 of formulas I, II and IV above, illustrative examples of a C2-C4 straight or branched alkyl include, but are not limited to, ethyl, propyl, isopropyl, butyl, and 2-butyl; illustrative example of a C6-C10 aryl group include, but are not limited to, phenyl, 1-naphthyl, 2-naphtlyl; illustrative examples of C5-C10 heterocyclic rings include, but are not limited to, piperidyl, pyrrolidyl, piperazyl, morpholine, tetahydrofuranyl, dioxanyl; illustrative examples of heteroaryl group include, but are not limited to, furanyl, thiophenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, dithiolyl, oxathiolyl, isoxazolyl, oxazolyl, thiazolyl, pyridinyl, piridazinyl, pyrimidinyl, pyrazinyl, , benzofuranyl, benzothiophenyl, indolyl, quinolinyl, isoquinolinyl, benzothiazoyl, benzimidazolyl, benzoxazinyl, benzothiadiazolyl, naphthyridinyl, pyrido[3,4-b]pyridinyl, pyrido[3,2- b]pyridinyl, pyrido[4,3-b]pyridinyl, and 4-aminopyrazolo[3,4-d]pyrimidinyl.
[013] Preferred embodiments for R2 include but are not limited to, 2-toluyl, 3- toluyl, 4-toluyl, 2,3-xylyl, 2,4-xylyl, 2,5-yiyl, 2,6-xylyl, 3,4-xylyl, 2,4,6-trimethylphenyl, 2- methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3-dimethoxyphenyl, 2,4- dimethoxyphenyl, 2,5-dimethoxyphenyl, 2,6-dimethoxyphenyl, 2-chlorophenyl, 3- chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2,5- dichlorophenyl, 2,6-dichlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3- difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl 2,3,5,6- tetrafluoro-3-cyanophenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 2,3- dicyanophenyl, 2,4-dicyanophenyl, 2,5-dicyanophenyl, 2,6-dicyanophenyl, 2- trifluoromethoxyphenyl, 3-trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, aminocarboxyphenyl, aminosulfonylphenyl.
[014] Illustrative examples of NR6R7 groups of formulas I, and III above, include, but are not limited to, N-cyclopropylmethyl-N-propylamino, piperazyl, piperidyl, pirimidyl, morpholyl, thiomorpholyl, oxazinanyl and thiazinanyl.
[015] A "subject" includes mammals, e.g., humans, companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like). In a preferred embodiment of the disclosed method, the subject is human. A subject in need of treatment is suffering from a disease or condition, the symptoms of which may be alleviated by inhibiting T-cell proliferation. Typically, a subject will be treated for a disease that is caused, at least in part, by or involves T-cell proliferation. Alternatively, the method is used to improve symptoms in a subject suffering from IBD, EAE, sepsis, rheumatoid arthritis or lupus. Preferably, the method is used to treat a subject that has IBD or sepsis.
[016] The compounds may be administered to a mammal in need of treatment by any route, such as oral, pulmonary, rectal, transdermal, subcutaneous, intravenous, intramuscular, intracranial, intraperitoneal and intranasal in combination with an acceptable pharmaceutical carrier, for tableting, solubilizing, or suspending in emulsion form or for delivering by slow release from a polymeric matrix. These carriers are well known in the art, however suitable carriers for the compounds of this invention are described below.
[017] An "effective amount" of a compound of the disclosed invention is the quantity which, when administered to a subject in need of treatment, improves the prognosis of the subject, e.g., delays the onset of and/or reduces the severity of one or more of the subject's symptoms. The amount of the disclosed compound to be administered to a subject will depend on the particular disease, the mode of administration, and the characteristics of the subject, such as general health, other diseases, age, sex, genotype, body weight and tolerance to drugs. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. Effective amounts of the disclosed compounds typically range between about 0.01 mg/kg per day and about 100 mg/kg per day, and preferably between 0.1 mg/kg per day and about 10 mg/kg/day.
[018] Preferably disclosed compounds or pharmaceutical formulations containing these compounds are in unit dosage form for administration to a subject. The unit dosage form can be any unit dosage form known in the art including, for example, a capsule, an I.V. bag, a tablet, a single pump on an aerosol inhaler, or a vial. The quantity of active ingredient (i.e., a compound of structural formula I or salts thereof) in a unit dose of composition is an effective amount and may be varied according to the particular treatment involved. It may be appreciated that it may be necessary to make routine variations to the dosage depending on the age and condition of the patient. The dosage will also depend on the route of administration which may be by a variety of routes as outlined above.
[019] A "pharmaceutically acceptable salt" of the disclosed compound can be used in the disclosed methods. For example, an acid salt of a compound containing an amine or other basic group can be obtained by reacting the compound with a suitable organic or inorganic acid, such as hydrogen chloride, hydrogen bromide, acetic acid, perchloric acid and the like. Compounds with a quaternary ammonium group also contain a counteranion such as chloride, bromide, iodide, acetate, perchlorate and the like. Other examples of such salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g. (+)-tartrates, (-)-tartrates or mixtures thereof including racemic mixtures), succinates, benzoates and salts with amino acids such as glutamic acid.
[020] The compounds described herein, and the pharmaceutically acceptable salts thereof can be used in pharmaceutical preparations in combination with a pharmaceutically acceptable carrier or diluent. Suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions. The compounds will be present in such pharmaceutical compositions in amounts sufficient to provide the desired dosage amount in the range described herein. Techniques for formulation and administration of the compounds of the instant invention can be found in Remington: the Science and Practice of Pharmacy, 19th edition, Mack Publishing Co., Easton, PA (1995). [021] For oral administration, the disclosed compounds or salts thereof can be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, pills, suppositories, powders, syrups, solutions, suspensions and the like.
[022] The tablets, pills, capsules, and the like contain from about 1 to about 99 weight percent of the active ingredient and a binder such as gum tragacanth, acacias, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch or alginic acid; a lubricant such as magnesium stearate; and/or a sweetening agent such as sucrose, lactose or saccharin. When a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.
[023] Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propyl parabens as preservatives, a dye and a flavoring such as cherry or orange flavor, and the like.
[024] For parenteral administration of the disclosed compounds, or salts thereof, can be combined with sterile aqueous or organic media to form injectable solutions or suspensions. For example, solutions in sesame or peanut oil, aqueous propylene glycol and the like can be used, as well as aqueous solutions of water-soluble pharmaceutically-acceptable salts of the compounds. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
[025] In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Suitable formulations of this type include biocompatible and biodegradable polymeric hydrogel formulations using crosslinked or water insoluble formulations of polysaccharides, polyethylene oxides, polyacrylates, and the like. Such long acting formulations may be administered by implantation, for example, subcutaneously or intramuscularly or by intramuscular injection. Preferably, they are implanted in the microenvironment of an affected organ or tissue. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials, for example, as an emulsion in an acceptable oil, or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
[026] In addition to the formulations described previously, the compounds may also be formulated as a topical preparation. Suitable formulations of this type include biocompatible oil, wax, gel, powder, polymer, or other liquid or solid carriers. Such formulations may be administered by applying directly to affected tissues. The compounds may also be formulated as suppositories. Suitable formulations include biocompatible wax.
[027] Preferred embodiments of the compounds of this inventions are outlined in the following tables with their in-vitro assay results assessing T-cell response.
Figure imgf000012_0001
Figure imgf000013_0001
Figure imgf000014_0001
Figure imgf000015_0001
Figure imgf000016_0001
Figure imgf000016_0002
Figure imgf000017_0001
Figure imgf000018_0001
Figure imgf000019_0001
Examples
Example 1 : General Synthetic Method 1 (compounds in Table 1 )
Et-NC + R2Q-NH2 → Et-NH-CO-NH-Q-R2 (II)
[028] To a stirred solution of amine (R2Q-NH2) in methylene chloride is added a solution of ethyl isocyanate (1.1 equivalents) in methylene chloride. The reaction is allowed to stir at room temperature overnight. The reaction is concentrated in-vacuo and the residue is dissolved in ethyl acetate. It is then washed successively with aqueous 1N hydrochloric acid, aqueous saturated sodium bicarbonate solution, brine, dried over sodium sulfate and concentrated.
Example 2: General Synthetic Method 2 (compounds in Table 2)
Et-NH-CO-NH-(CH2)3-Br + HNR6R7 → Et-NH-CO-NH-(CH2)3- NR6R7 (III)
[029] To a stirred solution of 1-(3'-bromopropyl)-3-ethyl urea in acetonitrile is added potassium carbonate (2.1 equivalents) and a secondary amine. The reaction is heated to reflux and allowed to stir overnight. The reaction is cooled to room temperature and partitioned between ethyl acetate and water. The organic layer is separated and washed with brine, dried over sodium sulfate and concentrated.
Example 3: General Synthetic Method 3 (compounds in Table 3)
Br-(CH2)3-NC + R2Q-NH2 → Br-(CH2)3-NH-CO-NH-Q-R2
[030] Step 1 : To a stirred solution of amine dissolved in methylene chloride at room temperature is added dropwise 3-bromopropyl isocyanate dissolved in methylene chloride. The reaction is allowed to stir overnight. The reaction was partitioned between methylene chloride and aqueous saturated sodium bicarbonate. The organic layer is separated, washed with brine, dried over sodium sulfate and concentrated.
Br-(CH2)3-NH-CO-NH-Q-R2+ Me2NH → Me2N-(CH2)3-NH-CO-NH-Q-R2 (IV) [031] Step 2: The product from Step 1 is dissolved in excess 2.0M dimethylamine in tetrahydrofuran. The reaction is warmed to 45°C and let stir overnight. The reaction is concentrated and partitioned between methylene chloride and aqueous saturated sodium bicarbonate. The organic layer is separated, washed with brine, dried over sodium sulfate and concentrated.
Example 4: Synthesis of Compound no.19 (compound in Table 1)
[032] To a stirred solution of 2-amino-5,6-dimethylbenzimidazole (484 mg, 3.0 mmol) in methylene chloride (10 ml) was added dropwise a solution of ethyl isocyanate (220 mg, 3.3 mmol) in methylene chloride (1 ml). The reaction was allowed to stir at room temperature overnight. The reaction was concentrated in-vacuo and the residue was dissolved in ethyl acetate (20 ml). It was then washed successively with aqueous 1N hydrochloric acid, aqueous saturated sodium bicarbonate, brine, dried over sodium sulfate and concentrated. The resulting solid was recrystallized from methanol/water to give 471 mg (68%) of a tan solid. 1H NMR (CDCI3) δ 7.08 (s, 1H), 7.02 (s, 1H), 3.47 (q, 2H), 2.24 (s, 3H), 2.22 (s, 3H), 1.30 (t, 3H) ppm.
Example 5: Synthesis of Compound no. 56 (Hydrochloride salt of Compound no. 19)
[033] To a stirred solution of 1 -(5,6-dimethyl-1 H-benzoimidazol-2-yl)-3-ethyl urea (1.46 g, 6.3 mmol) in acetone (30 ml) was bubbled in hydrogen chloride gas. A precipitate formed which was collected by filtration, washed with acetone and dried in a vacuum oven to give 1.35 g (80%) of an off-white solid.1H NMR (D2O) δ 6.88 (s, 1 H), 6.82 (s, 1H), 3.24 (q, 2H), 2.07 (s, 6H), 1.07 (t, 3H) ppm.
Example 6: Synthesis of Compound no. 31 (compound in Table 2)
[034] To a stirred solution of 1-(3'-bromopropyl)-3-ethyl urea (2.1 g, 10 mmol), see below, in acetonitrile (25 ml) was added potassium carbonate (2.9 g, 21 mmol) and 1-(2,3-xylyl)piperazine hydrochloride (2.27 g, 10 mmol). The reaction was heated to reflux and allowed to stir overnight. The reaction was cooled to room temperature and partitioned between ethyl acetate (40 ml) and water (30 ml). The organic layer was separated and washed with brine, dried over sodium sulfate and concentrated. Flash chromatography over silica gel (10:1 methylene chloride/2M ammonia in methanol) gave 1.21 g (38%) of an off white solid. 1H NMR (CDCI3) δ 7.08 (t, 1 H), 6.91 (dd, 2H), 5.31 (bs, 1 H), 4.98 (bs, 1 H), 3.28 (t, 2H), 3.21 (m, 2H), 2.91 (bs, 4H), 2.65 (bs, 4H), 2.54 (t, 2H), 2.26 (s, 3H), 2.21 (s, 3H), 1.72 (m, 2H), 1.14 (t, 3H) ppm.
Example 7: Synthesis of 1 -(3'-bromopropyl)-3-ethyl urea (precursor to Compound no. 31)
[035] To a stirred solution of 3-bromopropylamine hydrobromide (10.0 g, 45.7 mmol) in methylene chloride (100 ml) containing triethylamine (5.08 g, 50.2 mmol) was added ethyl isocyanate (3.24 g, 45.7 mmol) in methylene chloride (10 ml). Let stir at room temperature for 3 hours. The reaction was poured into aqueous 1N hydrochloric acid. The organic layer was separated and washed with brine, dried over sodium sulfate and concentrated to give 6.66 g (70%) of a white solid. 1H NMR (CDCI3) δ 3.41 (t, 2H), 3.29 (t, 2H), 3.20 (q, 2H), 2.05 (m, 2H), 1.14 (t, 3H) ppm.
Example 8: Synthesis of Compound no. 57 (Fumarate salt of Compound no. 31 )
[036] To a stirred solution of 1 -{3'-[4-(2,3-xylyl)-piperazin-1 -yl]-propyl}-3-ethyl urea (933 mg, 2.93 mmol) in acetone (15 ml)/methylene chloride (5 ml) was added fumaric acid (340 mg, 2.93 mmol) in acetone (30 ml) dropwise over 2 minutes. A precipitate formed which was collected by filtration, washed with acetone and dried in a vacuum oven to give 1.09 g (98%) of a white solid. 1H NMR (D2O) δ 6.99 (t, 1 H), 6.84 (m, 2H), 6.47 (s, 1 H), 3.45 (bd, 2H), 3.89 (m, 8H), 2.93 (q, 2H), 2.87 (m, 2H), 2.07 (s, 3H), 2.01 (s, 3H), 0.88 (t, 3H) ppm.
Example 9: Synthesis of Compound no. 42 (compound in Table 3)
[037] Step 1 : To a stirred solution of 1-aminoisoquinoline (2.5 g, 17.3 mmol) in methylene chloride (50 ml) was added 3-bromopropyl isocyanate (3.13 g, 19 mmol) dissolved in methylene chloride (15 ml). The mixture was allowed to stir at room temperature overnight. The mixture was partitioned between methylene chloride (20 ml) and aqueous saturated sodium bicarbonate (20 ml). The organic layer was separated and washed with brine, dried over sodium sulfate and concentrated to give 4.97 g of a brown solid (92%). This was used directly in the next step.
[038] Step 2: The 1-(3'-bromopropyl)-3-isoquinolin-1-yl urea from step 1 was dissolved in excess 2M dimethylamine in tetrahydrofuran (10 ml) in a sealed tube. Warmed to 50°C and let stir overnight. The reaction mixture was partitioned between diethyl ether (75 ml) and aqueous saturated sodium bicarbonate (25 ml). The organic layer was separated and washed with brine, dried over sodium sulfate and concentrated. Flash chromatography over silica gel (10:1 methylene chloride/2M ammonia in methanol) provided 3.12 g (70%) of an off-white solid. 1H NMR (CDCI3) δ 10.24 (bs, 1 H), 8.48 (bs, 1 H), 8.20 (d, 1 H), 8.03 (d, 1 H), 7.75 (d, 1 H), 7.69 (t, 1H), 7.60 (t, 1 H), 7.23 (d, 1 H), 3.52 (q, 2H), 2.43 (t, 2H), 2.28 (s, 6H), 1.87 (t, 2H) ppm.
Example 10: Synthesis of Compound 58 (Fumarate salt of Compound no. 49)
[039] The 1-(3'-dimethylaminopropyl)-3-isoquinolin-1-yl urea (417 mg, 1.53 mmol) from step 2 was dissolved in acetone (10 ml). With stirring, fumaric acid (180 mg, 1.55 mmol) dissolved in acetone (35 ml) was added dropwise over 2 minutes. A precipitate formed which was collected by filtration, washed with acetone and dried in a vacuum oven to give 260 mg (51%) of a white solid. 1H NMR (D2O) δ 8.91 (bd, 1 H), 7.82 (bs, 1 H), 7.67 (d, 1 H), 7.58 (t, 1 H), 7.47 (t, 1 H), 7.24 (bs, 1 H), 6.31 (s, 1 H), 3.24 (t, 2H), 3.04 (t, 2H), 2.71 (s, 6H), 1.85 (m, 2H) ppm.
Example 11: Cytokine Inhibition with compound no. 56 Table 5.
Figure imgf000024_0001
Example 12: Inflammatory Bowel Disease
[040] CM Hogaboam et al., Eur. J. Pharmacol.; 309; 261 (1996) [041] Groups of 3 derived-male, overnight-fasted rats weighing 150±10 g are used. Distal colitis is induced by intra-colonic instillation of 0.5 ml/rat of DNBS (2,4- dinitrobenzene sulfonic acid, 60 mg/ml in ethanol 30%) after which air (2 ml) is gently injected through the cannula to ensure that the solution remains in the colon. Test compound is administered orally 24 and 2 hours before DNBS instillation and then daily for 5 days in total of 7 doses. The animals are sacrificed 24 hours after the final dose of test compound administration and each colon is removed and weighed. A 30 percent or more (> 30%) inhibition in net increase of colon to 100g body weight ratio, relative to vehicle-control-2 group is considered significant.
[042] Compound no. 56 showed dose responsive activity and statistically significant response at the highest dose (25 mg/kg).
Figure imgf000025_0001
Example 13: Septic Shock, Lipopolysaccharide
KM Mohler et al., Nature; 370; 218 (1994).
[043] Groups of 4 or 6 C57/BL mice weighing 18-20g were used. Test substance at a dose of 25 and 5 mg/kg (10% cremophor/10% ethanol) is administered
IP one hour before challenge with lipopolysaccharide (LPS, from E. coli, LD100 of 20 ng/animal IV) plus galactosamine (20 mg/animal IV). The blank control group was only applied 10% cremophor/10% ethanol IP and without LPS challenge. Mortality is recorded every 12 hours after challenge over a 3-day period. Protection of mortality by 50 percent or more (> 50%) indicates significant activity.
[044] Compound no. 56 showed dose responsive activity and statistically significant response at the highest dose (25 mg/kg).
Figure imgf000026_0001
Example 14: Autoimmune encephalomyelitis (EAE) model Ref:
[045] The purpose of this study was to test the efficacy of several different small molecule compounds. Forty-eight female SJL/J mice, 8 weeks in age, were divided into nine test groups. Mice were immunized with proteolipid protein peptide
(PLP) 139-151 (50 μg/mouse) dissolved in PBS and emulsified with an equal volume of
Complete Freund's Adjuvent, supplemented with 4 mg/ml Mycobacterium tuberculosis
H37Ra, by injecting 100 μl s.c. in the lower abdominal area at two sites. Each mouse also received an injection of pertussis toxin (100 ng) into the tail vein immediately following immunization and again 48 hours later. The PLP 139-151 was supplied by Dr.
Vijay Kuchroo, Center of Neurological Diseases, Brigham & Women's Hospital, Boston,
MA.
[046] The animals were injected IP or PO daily with either compound or vehicle from day 1 to day 16. At the first sign of disease (day 9), each animal was assessed daily and given a disease severity score (ADSS) between 0 (no disease) and 5 (moribund or dead).
[047] Compound no. 56 dosed at 24 mg/kg had a significant effect on both disease onset and disease severity, as shown in Figure 2. Compound no. 57 dosed at 25 mg/kg had an effect on disease onset, but not on maximum severity, as shown in Figure 1.

Claims

im: 1. A compound of formula I: R1-NH-CO-NH-Q-R2 (I) or a pharmaceutically acceptable salt thereof, wherein R1 is a lower C2-C5 alkyl group, straight or branched chain and optionally substituted by an amino group of formula -NR3R4, wherein R3 and R4 are independently H, or C1-C3 alkyl group; Q is either a bond or a divalent C1-C5 straight or branched alkyl or alkenyl group; R2 is either one or more of the following groups g. H, adamantyl, -OH provided that R2 is not a bond, h. OR5, -COR5, -CO2R5 wherein R5 is a C1-C4 straight or branched alkyl group, i. C6-C10 aryl group, j. C5-C10 heteroaryl group wherein one or more ring positions may be occupied by N, S, or O, k. C5-C10 heterocyclic group wherein one or more ring positions may be occupied by N, S, or O, wherein the aryl, heteroaryl, or heterocyclic ring is unsubstituted or substituted by one or more of the following groups i. R5, -CN, Halogen, OR5, -COR5, -CO2R5, OCF3, -CONH2, -SO2NH2, and NO2, and I. NR6R7, wherein R6 and R7 are i. independently a C1 -C5 straight or branched alkyl or unsubstituted or substituted by -OH or cyclopropyl, phenyl ϋ. together with the N forming a 5 or 6 membered monocyclic ring having one or more ring positions occupied by another N, S, or O, wherein the heteroaryl ring thus formed is unsubstituted or substituted by one or more of the following groups 1. R5, -CN, halogen, OR5, -COR5, -CO2R5, OCF3, -CONH2, - SO2NH2, 2. C1-C5 alkyl or alkylene group substituted by an aryl group, and 3. C6 or C10 aryl or heteroaryl group unsubstituted or substituted by one ore more of R5, CF3, and halogen, wherein the aryl or hetero aryl may be a pending group off one position of, or a fused with, the NR6R7 ring. 2. The compound of claim 1 wherein R1 is ethyl. 3. The compound of claim 1 wherein R1 is dimethylaminopropyl. 4. The compound of claim 1 having Formula (III): Et-NH-CO-NH-(CH2)3- NR6R7. 5. The compound of claim 1 having the structure of
Figure imgf000029_0001
6. The compound of claim 1 having the structure of
Figure imgf000030_0001
7. The compound of claim 1 having the structure of
Figure imgf000030_0002
8. A method of treating an inflammatory condition or disease by administering an effective amount of a compound of any one of the preceding claim in a pharmaceutically acceptable carrier. 9. The method of claim 8, wherein the condition is inflammatory bowel disease, autoimmune encephalomyelitis, lupus, or sepsis. 10. The method of claim 8 wherein the carrier is buffered saline.
PCT/US2003/041470 2003-01-03 2003-12-23 Urea derivatives and their use as anti-inflammatory agents WO2004063181A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003303678A AU2003303678A1 (en) 2003-01-03 2003-12-23 Urea derivatives and their use as anti-inflammatory agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43795403P 2003-01-03 2003-01-03
US60/437,954 2003-01-03

Publications (1)

Publication Number Publication Date
WO2004063181A1 true WO2004063181A1 (en) 2004-07-29

Family

ID=32713255

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/041470 WO2004063181A1 (en) 2003-01-03 2003-12-23 Urea derivatives and their use as anti-inflammatory agents

Country Status (3)

Country Link
US (1) US7186725B2 (en)
AU (1) AU2003303678A1 (en)
WO (1) WO2004063181A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007093540A1 (en) * 2006-02-17 2007-08-23 F. Hoffmann-La Roche Ag Benzoyl-piperidine derivatives as 5ht2/d3 modulators
WO2007106525A1 (en) * 2006-03-13 2007-09-20 The Regents Of The University Of California Piperidinyl, indolyl, pirinidyl, morpholinyl and benzimidazolyl urea derivatives as inhibitors of soluble epoxide hydrolase for the treatment of hypertension, inflammations and other diseases
WO2008087366A2 (en) 2006-12-29 2008-07-24 Genfit Substituted 3-phenyl-1-(phenylthienyl)propan-1-one and 3-phenyl-1-(phenylfuranyl)propan-1-one derivatives, and preparation and use of same
US7662910B2 (en) 2004-10-20 2010-02-16 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
US7795437B2 (en) 2006-10-31 2010-09-14 Hoffmann-La Roche Inc. Ether derivatives
US8455652B2 (en) 2003-04-03 2013-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibitors for the soluble epoxide hydrolase
US8513302B2 (en) 2003-04-03 2013-08-20 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
US9296693B2 (en) 2010-01-29 2016-03-29 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
WO2018227300A1 (en) * 2017-06-14 2018-12-20 UNIVERSITé LAVAL Novel urea compounds and bioisosteres thereof and their use for treating inflammation and inflammation-related pathologies

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201329067A (en) * 2011-12-08 2013-07-16 Amgen Inc Urea compounds as GKA activators

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3061640A (en) * 1959-03-30 1962-10-30 Monsanto Chemicals 3, 4-dichlorophenyl dialkylaminoalkyl ureas and thioureas
GB1112034A (en) * 1964-05-04 1968-05-01 Eastman Kodak Co Merocyanine dyes,photographic silver halide emulsions containing them and multilayer photographic elements
JPS5192865A (en) * 1975-02-12 1976-08-14 SHASHUTSUSEIKEINYORUSUKASHIMOYOIRIGOSEIJUSHISEIYOKINO SEIHO
DE2847792A1 (en) * 1977-11-07 1979-05-10 Leo Pharm Prod Ltd N-4-CHINOLYL-GUANIDINE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS
EP0731099A1 (en) * 1995-03-06 1996-09-11 Bayer Ag N-(3-benzofuranyl)urea-derivatives
WO1999032463A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS
WO2000059490A2 (en) * 1999-04-06 2000-10-12 Genzyme Corporation Immunomodulating composition for use especially in the treatment of inflammations, infections and surgical adhesions
US6211235B1 (en) * 1996-11-22 2001-04-03 Elan Pharmaceuticals, Inc. Compounds for inhibiting β-amyloid peptide release and/or its synthesis
WO2002059081A2 (en) * 2001-01-26 2002-08-01 Kirin Beer Kabushiki Kaisha Urea derivatives as inhibitors of ccr-3 receptor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597902A (en) 1981-05-20 1986-07-01 A. H. Robins Company, Incorporated N-(arylthioalkyl)-N'-(aminoalkyl)ureas
US5527893A (en) 1987-09-18 1996-06-18 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US4937270A (en) 1987-09-18 1990-06-26 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US6174999B1 (en) 1987-09-18 2001-01-16 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US5017229A (en) 1990-06-25 1991-05-21 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US5057503A (en) 1989-01-23 1991-10-15 The Brigham And Women's Hospital Derivativized polysaccharides with biologic activity, method of their isolation, and uses therefor
US5356883A (en) 1989-08-01 1994-10-18 Research Foundation Of State University Of N.Y. Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use
US5622939A (en) 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
AU7705694A (en) 1993-10-04 1995-05-01 Glaxo Wellcome House Substituted urea and isothiourea derivatives as no synthase inhibitors
US5599984A (en) 1994-01-21 1997-02-04 The Picower Institute For Medical Research Guanylhydrazones and their use to treat inflammatory conditions
US5506151A (en) 1994-02-09 1996-04-09 Mitsubishi Kasei Corporation Non-specific reaction suppressor
US5700787A (en) 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5679654A (en) 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
CA2294064A1 (en) 1997-07-29 1999-02-11 Smithkline Beecham Corporation Il-8 receptor antagonists
JP3431467B2 (en) 1997-09-17 2003-07-28 株式会社東芝 High voltage semiconductor device
WO2000035449A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
BR0014651A (en) * 1999-10-20 2002-06-18 Tanabe Seiyaku Co Beta2-mediated cell adhesion inhibitors
SE9904046D0 (en) * 1999-11-09 1999-11-09 Goesta Lennart Flemmert Process for the continuous treatment of fluorine containment fumed silica and reactor for the implementation of this process
CA2699568C (en) * 1999-12-24 2013-03-12 Aventis Pharma Limited Azaindoles
MXPA02007632A (en) * 2000-02-07 2004-08-23 Abbott Gmbh & Co Kg 2 benzothiazolyl urea derivatives and their use as protein kinase inhibitors.

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3061640A (en) * 1959-03-30 1962-10-30 Monsanto Chemicals 3, 4-dichlorophenyl dialkylaminoalkyl ureas and thioureas
GB1112034A (en) * 1964-05-04 1968-05-01 Eastman Kodak Co Merocyanine dyes,photographic silver halide emulsions containing them and multilayer photographic elements
JPS5192865A (en) * 1975-02-12 1976-08-14 SHASHUTSUSEIKEINYORUSUKASHIMOYOIRIGOSEIJUSHISEIYOKINO SEIHO
DE2847792A1 (en) * 1977-11-07 1979-05-10 Leo Pharm Prod Ltd N-4-CHINOLYL-GUANIDINE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS
EP0731099A1 (en) * 1995-03-06 1996-09-11 Bayer Ag N-(3-benzofuranyl)urea-derivatives
US6211235B1 (en) * 1996-11-22 2001-04-03 Elan Pharmaceuticals, Inc. Compounds for inhibiting β-amyloid peptide release and/or its synthesis
WO1999032463A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS
WO2000059490A2 (en) * 1999-04-06 2000-10-12 Genzyme Corporation Immunomodulating composition for use especially in the treatment of inflammations, infections and surgical adhesions
WO2002059081A2 (en) * 2001-01-26 2002-08-01 Kirin Beer Kabushiki Kaisha Urea derivatives as inhibitors of ccr-3 receptor

Non-Patent Citations (44)

* Cited by examiner, † Cited by third party
Title
A. SHAFIEE ET AL.: "Synthesis and Pharmacological activity of Benzo[b]thiophene-3-carboxylic acid derivatives", J. PHARM. SCI., vol. 72, no. 2, 1983, pages 198 - 202, XP001189480 *
BORGNA ET AL., FARMACO ED. SCI., 33, 1978, pages 510 513 *
CAHOURS; HOFMANN, JUSTUS LIEBIGS ANN. CHEM., 102, 1875, pages 296 *
CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 33, no. 12, 1985, pages 5375 - 79 *
CHIMIJA, 57, 1962/63, pages 105, 107 *
CHITI, FARMACO ED. SCI., 15, 1960, pages 114 - 122 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KASAI, YASUHIKO ET AL: "Spectrophotometric determination of basic carbodiimide perchlorates by th use of ferric benzohydroxamate formation", XP002280893, retrieved from STN Database accession no. 105:17582 CA *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002280894, Database accession no. BRN 5223366, 5205423, 2833563 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002280895, Database accession no. Reaction ID 688564 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002280896, Database accession no. Reaction ID 1290602 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002280897, Database accession no. BRN 2655850 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002280898, Database accession no. Reaction ID 9203927 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002280899, Database accession no. BRN 8064736 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002280900, Database accession no. BRN 1222050 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002280901, Database accession no. Reaction ID 9084756 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002280902, Database accession no. Reaction ID 32297 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002280903, Database accession no. BRN 799410 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002280904, Database accession no. BRN 2101728 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002280905, Database accession no. Reaction ID 630163 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002280906, Database accession no. BRN 392384 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002280907, Database accession no. BRN 395838 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002280908, Database accession no. BRN 2117402 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002280909, Database accession no. Reaction ID 1404062 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002280910, Database accession no. BRN 2432164, 8396378 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002280911, Database accession no. BRN 218168 *
DIKSHOORN, RECL. TRAV. CHIM. PAYS-BAS, 48, 1928, pages 552 *
F. PERINI ET AL.: "Conversion of Ureidomalonates and 5-Carbalkoxyhydantoins into 5-Ureido-4,6-pyrimidinediones", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 35, no. 3, 1970, pages 812 - 16, XP002280891 *
FABIS, F. ET AL., TETRAHEDRON, vol. 54, no. 36, 1998, pages 10789 - 10800 *
G. CRANK ET AL: "Derivatives of 2-Aminooxazol Showing Antiinflammatory Activity", JOURNAL OF MEDICINAL CHEMISTRY, vol. 14, no. 11, 1971, pages 1075 - 1077, XP002280888 *
GOSTEA ET AL., REV. CHIM., 22, 1971, pages 711 *
HOF. H. ET AL., ARZNEIM. FORSCH., vol. 37, no. 3, 1987, pages 306 - 309 *
HONG ET AL., J. MED. CHEM., 16, 1973, pages 139 *
I. WEAVER ET. AL.: "Morpholinomethyl Derivatives of Urea and Substituted Urea", J. AMER. CHEM. SOC., vol. 66, no. 2, 1944, pages 222 - 225, XP002280892 *
IBRAHIM, IBRAHIM, J. CHEM. SOC. PERKIN TRANS 2, 1982, pages 1459 - 66 *
MASAKAZU FUJITA ET AL.: "Synthesis and Bioactivities of Novel Bicyclic Thiophenes and 4,5,6,7-Tetrahydrothieno[2,3-c]pyridines as Inhibitors of Tumor Necrosis Factor-.alpha. (TNF-.alpha.) Production", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 12, 2002, pages 1897 - 1900, XP002280889 *
MOCK, W. L. ET AL., J. CHEM. SOC. PERKIN TRANS 2, 4, 2002, pages 843 - 47 *
NOVIKOV, CHEM. HETEROCYCL. COMPD. (ENGL. TRANSL.), 4, 1968, pages 89 *
R. P. ALEXANDER ET AL.: "CDP840. A Prototype of a Novel Class of Orally Active Anti-Inflammatory Phosphodiesterase 4 Inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 12, 2002, pages 1451 - 56, XP002280890 *
RUDCHENKO, V. F. ET AL., BULL. RUSS. ACAD. SCI. DIC. CHEM. SCI. (ENGL. TRANSL.), vol. 41, no. 10.2, 1992, pages 1920 - 21 *
RUIZ-PEREZ, BEGONA ET AL: "Protection against lethal intra-abdominal sepsis by 1-(3- dimethylaminopropyl)-3-ethylurea", JOURNAL OF INFECTIOUS DISEASES, vol. 188, no. 3, 2003, pages 378 - 87, XP009031070 *
RYCZEK, J., J. HETEROCYCL. CHEM., vol. 35, no. 2, 2002, pages 997 - 1000 *
SAAVEDRA J. E. ET AL., ORG. PREP. PROCED. INT., vol. 24, no. 6, 1992, pages 655 - 60 *
SELLERI; CHITI, FARMACO ED. SCI., 12, 1957, pages 3, 11 *
SHEEHAN, J. C. ET AL., J. ORG. CHEM., 26, 1961, pages 2525 - 2528 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455652B2 (en) 2003-04-03 2013-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibitors for the soluble epoxide hydrolase
US8513302B2 (en) 2003-04-03 2013-08-20 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
US7662910B2 (en) 2004-10-20 2010-02-16 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
US8476043B2 (en) 2004-10-20 2013-07-02 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
US8415350B2 (en) 2006-02-17 2013-04-09 Hoffmann-La Roche Inc. Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors
WO2007093540A1 (en) * 2006-02-17 2007-08-23 F. Hoffmann-La Roche Ag Benzoyl-piperidine derivatives as 5ht2/d3 modulators
KR101062513B1 (en) 2006-02-17 2011-09-06 에프. 호프만-라 로슈 아게 Benzoyl-piperidine Derivatives as 5HT2 / D3 Modulators
US8039490B2 (en) 2006-02-17 2011-10-18 Hoffmann-La Roche Inc. Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors
JP4855485B2 (en) * 2006-02-17 2012-01-18 エフ．ホフマン−ラ ロシュ アーゲー Benzoyl-piperidine derivatives as 5HT2 / D3 modulators
US8501783B2 (en) 2006-03-13 2013-08-06 The Regents Of The University Of California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
AU2007225170B2 (en) * 2006-03-13 2012-11-01 The Regents Of The University Of California Piperidinyl, indolyl, pirinidyl, morpholinyl and benzimidazolyl urea derivatives as inhibitors of soluble epoxide hydrolase for the treatment of hypertension, inflammations and other diseases
US8188289B2 (en) 2006-03-13 2012-05-29 The Regents Of The University Of California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
JP2009530287A (en) * 2006-03-13 2009-08-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Piperidinyl, indolyl, pyrinidyl, morpholinyl and benzimidazolyl urea derivatives as inhibitors of soluble epoxide hydrolase for the treatment of hypertension, inflammation and other diseases
WO2007106525A1 (en) * 2006-03-13 2007-09-20 The Regents Of The University Of California Piperidinyl, indolyl, pirinidyl, morpholinyl and benzimidazolyl urea derivatives as inhibitors of soluble epoxide hydrolase for the treatment of hypertension, inflammations and other diseases
US9029550B2 (en) 2006-03-13 2015-05-12 The Regents Of The University Of California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
US7795437B2 (en) 2006-10-31 2010-09-14 Hoffmann-La Roche Inc. Ether derivatives
WO2008087366A2 (en) 2006-12-29 2008-07-24 Genfit Substituted 3-phenyl-1-(phenylthienyl)propan-1-one and 3-phenyl-1-(phenylfuranyl)propan-1-one derivatives, and preparation and use of same
US9296693B2 (en) 2010-01-29 2016-03-29 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
WO2018227300A1 (en) * 2017-06-14 2018-12-20 UNIVERSITé LAVAL Novel urea compounds and bioisosteres thereof and their use for treating inflammation and inflammation-related pathologies

Also Published As

Publication number Publication date
US20040180871A1 (en) 2004-09-16
AU2003303678A1 (en) 2004-08-10
US7186725B2 (en) 2007-03-06

Similar Documents

Publication Publication Date Title
SU843746A3 (en) Method of preparing aminothiazoles or their acid-additive salts
US7186725B2 (en) Anti-inflammatory compositions and methods
KR19980074060A (en) Novel substituted 3,4-dialkoxyphenyl derivatives
EP0017484A1 (en) 2-Imidazoline derivatives, process for the preparation thereof and the pharmaceutical composition of the same
EP0359311B1 (en) Butynylamine derivatives
US3632587A (en) Piperazino methyl isatinylidine 3 acetates
US6894052B1 (en) Diarylalkylpiperazines active on the lower urinary tract
EP0221511B1 (en) 2-aminosulfonyl-6-nitrobenzoic esters or amides, process for their preparation and pharmaceutical compositions containing them
US4522943A (en) Chemical compounds
GB2030985A (en) Substituted furans
US4526973A (en) Chemical compounds
KR20010022658A (en) 3-Substituted 3,4,5,7-Tetrahydro-Pyrrolo[3',4':4,5]Thieno[2,3-D]Pyrimidine Derivatives, Their Preparation and Use as 5HT Antagonists
RU2060249C1 (en) Polycyclic biocide compounds and pharmaceutical composition on their base
JPS6120536B2 (en)
US4367239A (en) Nitrosourea derivatives, pharmaceutical compositions thereof and method of preparation
US4503051A (en) Substituted 3-cyclobutene-1,2-diones, pharmaceutical compositions thereof and methods of use
CA1317956C (en) Basic-substituted 5-halo-thienoisothiazol-3(2h)-one 1, 1-dioxides, a process for the preparation thereof, and pharmaceutical preparations containing these compounds
EP0026989B1 (en) Nitrosourea derivatives, process for preparing them, and pharmaceutical compositions containing them
KR100508626B1 (en) Remedies/Preventives for frequent urination/Urinary incontinence and Tropone derivatives
RU2075477C1 (en) 1-[[2-(dilower alkylamino)alkyl]amino]-4-substituted thioxanthene-9-ones and pharmaceutical composition showing antitumor activity
US3742056A (en) Aromatic acet amidoxime-o-carbamates
US5190946A (en) Methods and compounds
US4647588A (en) 2-(substituted sulfamyl)-6-nitrobenzoic acid amides and pharmaceutical compositions
US4546188A (en) Substituted 1,2-diaminocyclobutene-3,4-diones
CS196399B2 (en) Process for preparing 2-substituted 1-/omega-amino-alkoxy/-benzenes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP